ArticlebioRxiv : the preprint server for biology2025
Melt Electrowritten Scaffold-Reinforced Affibody-Conjugated Hydrogels for Controlled Bone Morphogenetic Protein-2 Delivery.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Bone morphogenetic protein-2 (BMP-2) is clinically used to promote bone regeneration but suffers from uncontrolled release when delivered from collagen sponges, necessitating high doses that can cause adverse effects. Hydrogels offer tunable protein release but are limited by weak mechanics and poor stability during storage and handling. Here, we introduce a two-part protein delivery platform that integrates mechanical reinforcement with affinity-controlled protein release. We developed a melt electrowritten (MEW) scaffold-reinforced, affibody-conjugated polyethylene glycol maleimide (PEG-mal) hydrogel for affinity-controlled BMP-2 delivery. MEW scaffolds improved hydrogel handling, compressive resistance, and stability during lyophilization and rehydration, without altering bulk stiffness. Engineered BMP-2-specific affibodies provided affinity-based control over BMP-2 release. This ability to control BMP-2 release was preserved after lyophilization and rehydration of the hydrogels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.